Showing 6991-7000 of 8649 results for "".
- EyeDura's Sustained-Release Eye Drop Technology Wins Industry Honorshttps://modernod.com/news/eyeduras-sustained-release-eye-drop-technology-wins-industry-honors/2482886/EyeDura Therapeutics, developer of preservative-free sustained release ophthalmic therapies, announced it received top recognition at two major industry forums among a field of ophthalmic startup companies. EyeDura won 'The Winning Pitch' challeng
- Wayne Caulder Joins Bausch + Lomb as Vice President and General Manager, Surgical, UShttps://modernod.com/news/wayne-caulder-joins-bausch-lomb-as-vice-president-and-general-manager-surgical-us/2482881/Wayne Caulder has joined Bausch + Lomb as vice president and general manager, Surgical, US and Canada. Mr. Caulder brings more than 30 years of experience in the eye health industry across multiple therapeutic categories, including cataract and refractive surgery, retina and r
- The Vision Council Comments on Impact of Proposed Tariffs on Optical Industryhttps://modernod.com/news/the-vision-council-comments-on-impact-of-proposed-tariffs-on-optical-industry/2482880/The Vision Council has released a letter summarizing the recent tariffs proposed by the Trump administration and the impact it could have on the optical industry. The White House issued formal notice to several US trading partners outlining tariff
- Glaukos Receives EU MDR Certification for iStent infinite and iStent inject Whttps://modernod.com/news/glaukos-announces-european-union-mdr-certification-for-istent-infinite-and-istent-inject-w/2482868/Glaukos received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite, along with several of its other MIGS technologies, including iStent inject W. Glauko
- Opus Genetics' Presbyopia Drop Meets Primary Endpoint in VEGA-3 Phase 3 Trialhttps://modernod.com/news/opus-genetics-announces-vega-3-phase-3-trial-met-primary-endpoint-for-phentolamine-ophthalmic-solution-075-for-the-treatment-of-presbyopia/2482863/Opus Genetics announced positive topline results from VEGA-3, its second pivotal phase 3 trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. The VEGA-3 trial met its primary endpoint, with a statistically significant 27.2% of participants treated with phe
- ForSight Robotics Secures $125 Million in Series B Fundinghttps://modernod.com/news/forsight-robotics-secures-125-million-in-series-b-funding-addressing-global-surgeon-shortage-and-demand-for-ophthalmic-surgery/2482862/ForSight Robotics announced it has completed a $125M Series B round, led by Eclipse. The investment accelerates the next growth phase for the ORYOM Platform, the world’s first robotic surgery platform for cataract and other eye diseases designed to enhance surgical precision, incr
- Hadley and Notal Vision Partner to Empower Patients With Vision Loss Through Education and Leading Technologyhttps://modernod.com/news/hadley-and-notal-vision-partner-to-empower-patients-with-vision-loss-through-education-and-leading-technology/2482860/Hadley and Notal Vision announced a strategic partnership to bridge the gap between early detection, treatment monitoring, and adaptive living for patients with age-related macular degeneration (AMD). The collaboration will connect users of Notal Vision’s ForeseeHome and SCANLY Ho
- Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congresshttps://modernod.com/news/qlaris-bio-to-present-new-clinical-and-preclinical-data-on-qls-111-at-2025-world-glaucoma-congress/2482859/Qlaris Bio announced that new data from studies of its lead investigational compound QLS-111 will be presented at the 2025 World Glaucoma Congress (WGC). This will include an oral presentation on clinical data from the recently completed QC-111-201 “Osprey” and QC-111-203 “
- EyeCare4Kids Names Maggie Cline as New CEOhttps://modernod.com/news/eyecare4kids-names-maggie-cline-as-new-ceo/2482838/The non-profit EyeCare4Kids announced the promotion of Maggie Cline, MPH, to Chief Executive Officer (CEO). Ms. Cline joined EyeCare4Kids in 2022 and served as Executive Director Utah, where she oversaw the delivery of more than 50,000 vision services annually at school clinics, community centers
- Rare Pediatric Disease Designation Granted for Ocugen's Gene Therapy for the Treatment of Stargardt Diseasehttps://modernod.com/news/rare-pediatric-disease-designation-granted-for-ocugens-gene-therapy-for-the-treatment-of-stargardt-disease/2482831/Ocugen announced that the FDA has granted Rare Pediatric Disease Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. Previously, OCU410ST received Orphan Drug designations